Mount Sinai's Icahn School of Medicine jumps into Dx, drug development

The Icahn School of Medicine at Mount Sinai in New York will team with a Massachusetts biopharmaceutical company to develop new diagnostics and drugs for cancer, plus central nervous system and endocrine disorders. Its 5-year partnership with Berg is expected to focus, in part, on developing diagnostic tools that can spot disease better and also mark how well a treatment is working. They'll pursue projects in areas including genomics, proteomics, lipidomics and metabolomics. Item

Suggested Articles

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.

Cybernet Manufacturing, maker of medical-grade computer monitors, has unveiled a new, large touchscreen designed to protect against infections.

A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in complications.